Orforglipron UK: Availability and Access Questions

• GPhC registered UK pharmacy and weight loss clinic, registration number 9012878
• Online consultation with UK registered prescribers for weight management
• Independent prescriber review and clinical assessment before any supply
• Genuine UK sourced medicines and ongoing clinical support

Orforglipron is licensed in the UK. The Medicines and Healthcare products Regulatory Agency, the MHRA, authorised it on 10 August 2026, making the UK the first country in Europe to approve this once daily GLP-1 tablet. It is authorised for weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight related health condition, alongside a reduced calorie diet and increased physical activity, and it is also authorised to improve blood sugar control in adults with insufficiently controlled type 2 diabetes. It is a prescription only medicine, and it is supplied in the UK on private prescription through registered pharmacies after a clinical assessment.

That answers the two questions people search for, but it leaves the ones that matter: who qualifies, what the assessment involves, what the trial evidence shows, what the tablet does and does not do differently from the injectable medicines, and how to obtain it without falling for the counterfeit and unlicensed sellers that follow every new weight loss medicine. This guide from the EveryDayMeds pharmacy team answers each in turn.

Is orforglipron available in the UK?

Yes. Orforglipron has UK marketing authorisation following the MHRA's decision on 10 August 2026. Private availability depends on supply, prescribing arrangements and pharmacy stock. The National Institute for Health and Care Excellence (NICE), which assesses new medicines separately from the MHRA, is expected to publish its own guidance on orforglipron, and that guidance does not affect whether a registered prescriber can prescribe it privately now, although NHS eligibility for Foundayo is not yet confirmed because NICE guidance is still pending.

Key things to know

• Orforglipron is a GLP-1 receptor agonist, as is semaglutide; tirzepatide acts on both GIP and GLP-1 receptors.
• The MHRA has authorised it for weight management in adults with a BMI of 30 or above, or 27 to 30 with a weight related condition, with diet and physical activity, and for insufficiently controlled type 2 diabetes.
• It is a prescription only medicine. Anyone selling it without a prescription is breaking the law, and a product sold that way cannot be trusted to be genuine.
• In ATTAIN-1, the treatment-regimen analysis found an average weight change of −11.2% at 72 weeks with the 36 mg dose, compared with −2.1% with placebo. In a separate efficacy estimand analysis, the corresponding figures were −12.4% and −0.9%
• Side effects are mainly digestive, typically nausea, vomiting, constipation and diarrhoea, most often when starting or increasing the dose, and the MHRA has said it will keep the medicine's safety under close review.
• It is taken once a day at any time, with no food or water restrictions, which is one of the practical differences from the oral form of semaglutide.
• Treatment suitability depends on an individual clinical assessment, and your prescriber will determine the appropriate treatment.

What is orforglipron?

Orforglipron is a small molecule GLP-1 receptor agonist. GLP-1 is a natural hormone the body releases after eating that acts on appetite centres in the brain, slows the stomach's emptying and helps explain how does foundayo work by regulating blood sugar levels, including by increasing insulin release when blood sugar levels are high.

Medicines that mimic it reduce hunger and increase fullness, which is how they support weight loss when combined with a reduced calorie diet and more activity. Semaglutide and tirzepatide are peptide medicines, which stomach acid would break down, so they are given by injection or, in the case of oral semaglutide, sometimes searched for by patients as the wegovy pill, in a tablet with strict fasting rules.

Foundayo orforglipron is not a peptide, so the foundayo pill is available in the UK as a once-daily tablet and does not require fasting before or after dosing. Its UK brand name is Foundayo.

Who can get orforglipron in the UK?

Orforglipron can be prescribed for adults who meet the licensed criteria and pass a clinical assessment, and it is not prescribed on request alone.

What does the assessment check?

The assessment checks that you meet the licensed criteria, that the medicine is safe for you, and that it is being used within a plan that includes diet and activity. A prescriber will usually ask about the following, and may ask for measurements, photographs or recent test results to confirm them.

1. Height, weight and BMI, and any weight related conditions such as high blood pressure, raised cholesterol, sleep apnoea or type 2 diabetes.
2. Your medical history, including pancreatitis, gallbladder disease, thyroid conditions, kidney or liver problems, and eating disorders.
3. Other medicines, because a GLP-1 medicine slows stomach emptying and can change how some tablets are absorbed, and because some medicines need adjusting alongside it. You should tell the clinical team about all medicines you use, and this is especially important before surgery or procedures.
4. Pregnancy, breastfeeding and plans to conceive, since GLP-1 medicines are not used in pregnancy and are stopped beforehand.
5. Previous weight loss treatment, including any injectable GLP-1 medicine, and how it went.
6. What you have already tried with diet and activity, and what support you will have during treatment.
7. Your goals and expectations, so the plan is realistic and results are reviewed against them.

A prescriber will decline where the criteria are not met, where a condition makes the medicine unsafe, or where a request is for a use outside the licence, and will explain why. A healthcare provider may also advise on treatment pauses, possible interactions, or what to do if doses are missed repeatedly.

What does the evidence show?

The evidence comes mainly from the ATTAIN programme clinical trials, and the UK licence for weight management rests on them. ATTAIN-1 randomised 3,127 adults with obesity, or overweight with a weight related condition, and without diabetes, to one of three daily doses of orforglipron or placebo for 72 weeks, alongside diet and activity advice.

These results show participants could lose weight from their starting body weight, with orforglipron linked to meaningful weight loss and around 2 to 5 times greater loss than diet alone or placebo depending on dose. The trial also reported improvements in waist circumference, blood pressure, cholesterol and blood sugar measures compared with placebo. The lower doses produced smaller average losses.

How does that compare with injectable medicines?

Published trials of injectable semaglutide and tirzepatide have reported different average weight reductions, but these figures should not be treated as a direct comparison because the medicines have not been compared head-to-head in this setting and the trials differed in design and populations. Trials differ in their participants, their length and their analysis, and a prescriber weighs the tablet's convenience against these injectable treatments, often grouped by patients as weight loss injections, for each person. Your prescriber will determine the appropriate treatment. This section explains how Foundayo compares with other GLP 1 treatments and wider weight loss treatments, rather than declaring a winner.

How is orforglipron different from other weight loss medicines?

Orforglipron differs in how it is taken more than in how it works compared with other weight loss treatments. The table sets out the practical differences without ranking the medicines.

Dose steps are decided by the prescriber according to the licence and how you tolerate the medicine. The top step is the maximum dose, while longer-term prescribing may continue at a maintenance dose set for you. They are not something to speed up or manage yourself, and a missed dose is not made up by doubling the next one. Follow the patient information leaflet.

What are the side effects and risks?

Like other GLP-1 medicines, orforglipron can cause side effects, with digestive symptoms being the most common. In the ATTAIN-1 trial, the most frequently reported side effects included nausea, constipation, diarrhoea and vomiting. These effects were generally mild to moderate and were more common during treatment.

The frequency of individual side effects was considerably higher than 6–10%, so it would be misleading to describe digestive problems as occurring in only that proportion of people. Some participants also stopped treatment because of side effects; in ATTAIN-1, adverse events led to treatment discontinuation in approximately 5% to 10% of participants receiving orforglipron, depending on the dose.

Other side effects reported with orforglipron include decreased appetite, indigestion, abdominal symptoms, fatigue and dizziness. If side effects become troublesome, particularly during dose increases, speak to your prescriber rather than changing the dose or stopping treatment yourself.

As with other medicines used for weight management, your prescriber will consider your medical history, other medicines and how you are responding to treatment when deciding whether to continue or adjust treatment. The MHRA is continuing to monitor the safety and effectiveness of orforglipron.

What are the serious risks?

The serious risks are those recognised for the GLP-1 class, and they are the reason for the medical history questions above. Because these medicines affect the digestive system, symptoms such as nausea, reflux or bowel upset can occur and often improve as the body adjusts.

• Pancreatitis. Severe, persistent abdominal pain, stomach pain, sometimes spreading to the back, with or without vomiting, needs urgent medical attention and the medicine should be stopped while it is assessed.
• Gallbladder problems. Rapid weight loss and GLP-1 medicines are both associated with gallstones. Pain under the right ribs, fever or yellowing of the skin or eyes needs a doctor.
• Dehydration and kidney problems from prolonged vomiting or diarrhoea. Keep fluids up and seek advice if you cannot keep them down.
• Low blood sugar in people also taking insulin or certain diabetes tablets, which may need adjusting.
• Thyroid tumours seen in animal studies of GLP-1 medicines. The relevant UK product information should be checked for thyroid-related contraindications and warning
• Pregnancy, breastfeeding and contraception

Orforglipron should not be used during pregnancy. If you are pregnant, planning to become pregnant or breastfeeding, tell your prescriber before starting treatment. Your prescriber can explain whether treatment should be stopped and what timing is appropriate if you are planning a pregnancy.

Do not assume that contraception advice is the same for every GLP-1 medicine. Orforglipron-specific advice should be followed from the current UK Patient Information Leaflet and Summary of Product Characteristics, and your prescriber or pharmacist can advise you about your particular contraceptive method. The MHRA recommends checking the product information for medicine-specific advice on pregnancy and contraception.

How do you get orforglipron safely in the UK?

You get Foundayo safely through a registered UK pharmacy, after an assessment by a registered prescriber, with a private prescription and a plan for follow up. Every part of that sentence protects you.

1. Check the pharmacy is registered. Every UK pharmacy, including online ones, must be on the GPhC register, which can be searched by name or registration number. The prescriber is registered with their own regulator.
2. Expect an assessment. A consultation that asks about weight, health conditions, medicines and pregnancy is the sign of a legitimate service. A site that sells the tablet on a form with no questions is not one.
3. Expect a prescription. Orforglipron is one of the prescription-only medicines. There is no legal over the counter supply and no legal sale without a prescriber's decision.
4. Expect genuine, UK licensed stock. Check that the pharmacy is appropriately registered and that the medicine supplied is the authorised UK product, with the appropriate packaging and patient information leaflet.Medicines obtained from unregulated websites, social media accounts or marketplaces may be counterfeit, unlicensed, incorrectly dosed or contain undeclared ingredients.
5. Expect follow up. Dose steps, side effects and results are reviewed. A service that supplies a supply and disappears is not providing treatment.

What are the warning signs of an unsafe seller?

• No consultation, or a consultation that can be completed in seconds with no medical questions.
• No mention of the GPhC or a registration number that cannot be found on the register.
• Supply offered to people who do not meet the licensed criteria, or to children.
• Claims of guaranteed weight loss, a specific number of kilograms, or a cure.
• Packaging or product information that does not correspond with the authorised UK product.
• Pressure to buy a long supply up front.

The MHRA has repeatedly warned about counterfeit and unlicensed weight loss medicines sold online. If you have bought a product you now doubt, do not take it, and report it through the MHRA's Yellow Card scheme.

What happens once treatment starts?

Treatment starts at a low dose and is gradually increased in steps by the prescriber to help your body adjust, with regular review against your results, side effects and plan for diet and activity. The tablet is taken once a day at any time, with or without food. Diet, physical activity and longer-term weight-management support remain important throughout treatment and when treatment is stopped.

What commonly goes wrong?

• Stopping at the first nausea. Digestive effects usually peak at dose changes and often settle. Tell your prescriber rather than stopping.
• Skipping the diet and activity part. The licence and the trial both assume them.
• Comparing your first month with a 72 week trial figure.
• Doubling a missed dose. Never. Follow the leaflet.
• Not mentioning other medicines, including diabetes medicines and contraceptives.
• Buying from an unregistered seller to avoid an assessment.

How can EveryDayMeds help?

EveryDayMeds is a GPhC registered UK pharmacy and weight loss clinic, registration number 9012878, and our online consultation with UK registered prescribers assesses eligibility for GLP-1 based weight management treatment, including wider GLP-1 treatments where appropriate, against the licensed criteria. An independent prescriber reviews your answers before anything is supplied, decides which medicine is appropriate, and sets the dose steps and review points. Ask whether orforglipron is available through our clinic at the time of your consultation, because availability of a newly launched medicine can change, and the prescriber will discuss the alternatives if it is not.

Medicines are supplied through the regulated pharmacy supply chain and provided with the applicable patient information.

Medical Disclaimer

This article is for general information only and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. It does not recommend any specific medicine or dose. Orforglipron is a prescription only medicine that should only be used under the supervision of an appropriately qualified prescriber, within its UK licence. Always read the patient information leaflet. If you have severe abdominal pain, cannot keep fluids down, or notice yellowing of the skin or eyes, seek urgent medical attention.